The estimated Net Worth of Wolf Capital Limited Part... is at least $6.9 Milhão dollars as of 26 May 2021. Wolf Part owns over 355,570 units of Pluri Inc stock worth over $3,121,918 and over the last 4 years Wolf sold PSTI stock worth over $3,774,293.
Sign up
Wolf Part PSTI stock SEC Form 4 insiders trading
Wolf has made over 16 trades of the Pluri Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Wolf sold 355,570 units of PSTI stock worth $1,315,609 on 26 May 2021.
The largest trade Wolf's ever made was buying 700,449 units of Pluri Inc stock on 27 May 2020 worth over $5,330,417. On average, Wolf trades about 157,622 units every 23 days since 2020. As of 26 May 2021 Wolf still owns at least 3,121,918 units of Pluri Inc stock.
You can see the complete history of Wolf Part stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Wolf Part's mailing address?
Wolf's mailing address filed with the SEC is 24 BODENHIMER STREET, , TEL AVIV,, L3, 6200838.
Insiders trading at Pluri Inc
Over the last 17 years, insiders at Pluri Inc have traded over $7,081,854 worth of Pluri Inc stock and bought 2,345,914 units worth $14,327,834 . The most active insiders traders include Wolf Capital Limited Part..., Zami Aberman, eIsrael Ben Yoram. On average, Pluri Inc executives and independent directors trade stock every 64 days with the average trade being worth of $54,123. The most recent stock trade was executed by Zami Aberman on 10 February 2022, trading 80,616 units of PSTI stock currently worth $145,109.
What does Pluri Inc do?
Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a
What does Pluri Inc's logo look like?
Complete history of Wolf Part stock trades at Pluri Inc
Pluri Inc executives and stock owners
Pluri Inc executives and other stock owners filed with the SEC include:
-
Yaacov Yanay,
Pres, CEO & Director -
Zalman Aberman,
Executive Chairman of the Board -
Yaky Yanay,
President, Chief Executive Officer, Director -
Chen Franco-Yehuda,
Chief Financial Officer, Treasurer, Secretary -
Dana Rubin,
Director of Investor Relations -
Moria Kwiat,
Independent Director -
Mark Germain,
Independent Director -
Isaac Braun,
Independent Director -
Doron Shorrer,
Lead Independent Director -
Dr. Nitsan Halevy M.D.,
Chief Medical Officer -
Efrat Livne-Hadass,
VP of HR -
Lior Raviv,
Chief Technology Officer -
Israel Ben Yoram,
Director -
Nachum Rosman,
Director -
Hava Meretzki,
Director -
Erez Egozi,
Chief Financial Officer -
Shai Pines,
Director -
Boaz Gur Lavie,
CFO -
Wolf Capital Limited Part...,
10% owner -
Maital Shemesh Rasmussen,
Director -
Rami Avraham Levi,
Director -
Pinhas Doron Birger,
Director -
Varda Shalev,
Director -
Zami Aberman,
Director